These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37770938)

  • 1. Serum neurofilament light chain in COVID-19 and the influence of renal function.
    Körtvelyessy P; Diekämper E; Ruprecht K; Endres M; Stubbemann P; Kurth F; Graw JA; Menk M; Kuhle J; Wohlrab F
    Eur J Med Res; 2023 Sep; 28(1):389. PubMed ID: 37770938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum neurofilament light chain levels in Covid-19 patients without major neurological manifestations.
    Verde F; Milone I; Bulgarelli I; Peverelli S; Colombrita C; Maranzano A; Calcagno N; Ticozzi N; Perego GB; Parati G; Torresani E; Ratti A; Silani V
    J Neurol; 2022 Nov; 269(11):5691-5701. PubMed ID: 35781535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study.
    Abdelhak A; Petermeier F; Benkert P; Schädelin S; Oechtering J; Maleska Maceski A; Kabesch M; Geis T; Laub O; Leipold G; Gobbi C; Zecca C; Green A; Tumani H; Willemse E; Wiendl H; Granziera C; Kappos L; Leppert D; Waubant E; Wellmann S; Kuhle J
    Lancet Neurol; 2023 Sep; 22(9):826-833. PubMed ID: 37524100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis-a cross-sectional multicenter study.
    Meyer T; Salkic E; Grehl T; Weyen U; Kettemann D; Weydt P; Günther R; Lingor P; Koch JC; Petri S; Hermann A; Prudlo J; Großkreutz J; Baum P; Boentert M; Metelmann M; Norden J; Cordts I; Weishaupt JH; Dorst J; Ludolph A; Koc Y; Walter B; Münch C; Spittel S; Dreger M; Maier A; Körtvélyessy P
    Eur J Neurol; 2023 Jun; 30(6):1600-1610. PubMed ID: 36899448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Neurofilament light chain (NfL) levels in children with and without neurologic diseases.
    Geis T; Gutzeit S; Fouzas S; Ambrosch A; Benkert P; Kuhle J; Wellmann S
    Eur J Paediatr Neurol; 2023 Jul; 45():9-13. PubMed ID: 37236127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19.
    Geis T; Brandstetter S; Toncheva AA; Laub O; Leipold G; Wagner R; Kabesch M; Kasser S; Kuhle J; Wellmann S;
    J Neurol; 2021 Nov; 268(11):3969-3974. PubMed ID: 33893540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting.
    Seiberl M; Feige J; Hilpold P; Hitzl W; Machegger L; Buchmann A; Khalil M; Trinka E; Harrer A; Wipfler P; Moser T
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Neurofilament Light Chain Levels Are Associated with Clinical Characteristics and Outcome in Patients with Cervical Artery Dissection.
    Traenka C; Disanto G; Seiffge DJ; Gensicke H; Hert L; Grond-Ginsbach C; Peters N; Regeniter A; Kloss M; De Marchis GM; Bonati LH; Lyrer PA; Kuhle J; Engelter ST
    Cerebrovasc Dis; 2015; 40(5-6):222-7. PubMed ID: 26418549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
    Buchmann A; Pirpamer L; Pinter D; Voortman M; Helmlinger B; Pichler A; Maceski AM; Benkert P; Bachmaier G; Ropele S; Reindl M; Leppert D; Kuhle J; Enzinger C; Khalil M
    Eur J Neurol; 2023 May; 30(5):1389-1399. PubMed ID: 36779855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Huppke B; Reinert MC; Hummel-Abmeier H; Stark W; Gärtner J; Huppke P
    Neurology; 2023 Nov; 101(19):e1873-e1883. PubMed ID: 37748882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis.
    Fujimori J; Nakashima I
    J Neurol Sci; 2021 Aug; 427():117528. PubMed ID: 34098375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
    Dietmann AS; Kruse N; Stork L; Gloth M; Brück W; Metz I
    J Neurol; 2023 Mar; 270(3):1416-1429. PubMed ID: 36372867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament light chain and glial fibrillary acid protein levels are elevated in post-mild COVID-19 or asymptomatic SARS-CoV-2 cases.
    Plantone D; Stufano A; Righi D; Locci S; Iavicoli I; Lovreglio P; De Stefano N
    Sci Rep; 2024 Mar; 14(1):6429. PubMed ID: 38499607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice.
    Valentino P; Marnetto F; Martire S; Malucchi S; Bava CI; Popovic M; Bertolotto A
    Mult Scler Relat Disord; 2021 Sep; 54():103090. PubMed ID: 34182224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
    Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J;
    Lancet Neurol; 2022 Mar; 21(3):246-257. PubMed ID: 35182510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis.
    McComb M; Krikheli M; Uher T; Browne RW; Srpova B; Oechtering J; Maceski AM; Tyblova M; Jakimovski D; Ramasamy DP; Bergsland N; Krasensky J; Noskova L; Fialova L; Weinstock-Guttman B; Havrdova EK; Vaneckova M; Zivadinov R; Horakova D; Kuhle J; Ramanathan M
    J Clin Lipidol; 2020; 14(5):675-684.e2. PubMed ID: 32758395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients.
    Valentino P; Malucchi S; Bava CI; Martire S; Capobianco M; Malentacchi M; Sperli F; Oggero A; Di Sapio A; Bertolotto A
    Mult Scler Relat Disord; 2023 Sep; 77():104893. PubMed ID: 37481820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D supplementation and serum neurofilament light chain in interferon-beta-1b-treated MS patients.
    Hänninen K; Jääskeläinen O; Herukka SK; Soilu-Hänninen M
    Brain Behav; 2020 Sep; 10(9):e01772. PubMed ID: 32705821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum neurofilament levels and patient-reported outcomes in multiple sclerosis.
    Galetta K; Deshpande C; Healy BC; Glanz B; Ziehn M; Saxena S; Paul A; Saleh F; Collins M; Gaitan-Walsh P; Castro-Mendoza P; Weiner HL; Chitnis T
    Ann Clin Transl Neurol; 2021 Mar; 8(3):631-638. PubMed ID: 33492760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.